复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center

该疾病的证据

依据官方公开数据来源筛选

1. Colorectal cancer

   Shanghai 上海市

   已发表研究

   • Eggerthella lenta disrupts the gut vascular barrier to drive colorectal cancer liver metastasis. Cell discovery, 2026
   • E3 ubiquitin ligase COP1-mediated GSK3β degradation activates β-catenin signaling to facilitate colorectal cancer cell proliferation. Acta biochimica et biophysica Sinica, 2026

   另有 3 项已发表研究

   PubMed 收录了 5 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 Thoracic Surgery #10, Medical Oncology #3, 核医学 获提名。

2. Breast cancer

   Shanghai 上海市

   已发表研究

   • Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer. Targeted oncology, 2026
   • High-Density Type I Collagen Promotes IFN-γ(+) CD8(+) T Cell Exhaustion via SAT1-ASS1-Mediated Glutamine Accumulation and Ferroptosis in Triple-Negative Breast Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026

   另有 4 项已发表研究

   PubMed 收录了 6 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 Thoracic Surgery #10, Medical Oncology #3, 核医学 获提名。

3. Lung cancer

   Shanghai 上海市

   复旦专科声誉排行榜 2023

   • Thoracic Surgery #10 https://www.fdygs.com/news2023-1.aspx

   同时上榜：在复旦榜中为 Medical Oncology #3, 核医学 获提名。

4. Liver cancer

   Shanghai 上海市

   国家临床重点专科

   • Hepatobiliary Surgery（B 级） https://www.shca.org.cn/home/news/content/id/297/pid/25651

   已发表研究

   • The conversion window in hepatocellular carcinoma: When resectability alone is not an indication for surgery. Drug discoveries & therapeutics, 2026
   • Combination of programmed death protein-1 inhibitor improves the efficacy of transarterial chemoembolization plus lenvatinib for unresectable intermediate-stage hepatocellular carcinoma: a real-world multi-center retrospective study. European journal of radiology, 2026

   PubMed 收录了 2 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 Thoracic Surgery #10, Medical Oncology #3, 核医学 获提名。

5. Stomach cancer

   Shanghai 上海市

   已发表研究

   • Single-cell transcriptomics reveals CD8 + T-cell heterogeneity linked to immunotherapy response in gastric cancer. Biochemical and biophysical research communications, 2026

   PubMed 收录了 1 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 Thoracic Surgery #10, Medical Oncology #3, 核医学 获提名。

6. Esophageal cancer

   Shanghai 上海市

   复旦专科声誉排行榜 2023

   • Thoracic Surgery #10 https://www.fdygs.com/news2023-1.aspx

   已发表研究

   • A Prospective Multicenter Comparative Cohort Study of Neoadjuvant Sintilimab Plus Chemotherapy and Chemoradiotherapy in Resectable Clinical Node-Positive Esophageal Squamous Cell Carcinoma. Annals of surgical oncology, 2026
   • ASO Author Reflections: Can Immunochemotherapy Redefine Neoadjuvant Treatment for Node-Positive Esophageal Squamous Cell Carcinoma? Annals of surgical oncology, 2026

   另有 1 项已发表研究

   PubMed 收录了 3 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 Medical Oncology #3, 核医学 获提名。

7. Pancreatic cancer

   Shanghai 上海市

   复旦专科声誉排行榜 2023

   • Medical Oncology #3 https://www.fdygs.com/news2023-1.aspx

   国家临床重点专科

   • Medical Oncology（B 级） https://www.shca.org.cn/home/news/content/id/297/pid/25651
   • Hepatobiliary Surgery（B 级） https://www.shca.org.cn/home/news/content/id/297/pid/25651

   同时上榜：在复旦榜中为 Thoracic Surgery #10, 核医学 获提名。

8. Liver transplantation

   Shanghai 上海市

   国家临床重点专科

   • Hepatobiliary Surgery（B 级） https://www.shca.org.cn/home/news/content/id/297/pid/25651

   同时上榜：在复旦榜中为 Thoracic Surgery #10, Medical Oncology #3, 核医学 获提名。

9. Bone and soft tissue sarcoma

   Shanghai 上海市

   复旦专科声誉排行榜 2023

   • Medical Oncology #3 https://www.fdygs.com/news2023-1.aspx

   国家临床重点专科

   • Medical Oncology（B 级） https://www.shca.org.cn/home/news/content/id/297/pid/25651

   同时上榜：在复旦榜中为 Thoracic Surgery #10, 核医学 获提名。